# | ||||
---|---|---|---|---|
1 | ANTBIOTIC AnTBiotic – progressing TB drug candidates to clinical proof of concept | 2017 | 5˙819˙416.00 | 5˙819˙416.00 |
2 | LYMPHVECS Development of lipid nanoparticles based on solid matrix for Benznidazole oral delivery targeting to the lymphatic system to treat Chagas disease | 2019 | 158˙121.00 | 158˙121.00 |
The Institution GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL has been involved also in the following Horizon 2020 projects.